PURPOSE: Moderate deep inspiration breath-hold (mDIBH), using an Active Breathing Control device, has been used in our clinic since 2002 to reduce cardiac dose for patients receiving left-sided breast irradiation. We report our routine use of the mDIBH technique in clinically localized breast cancer, treated to the intact breast, reconstructed breast, or chest wall. MATERIALS AND METHODS: Ninety-nine patients with left-sided breast cancer were evaluated for Active Breathing Control treatment, of which, 87 patients were treated with mDIBH. Plans for both the free-breathing (FB) and mDIBH computed tomography scans were evaluated. Dose-volume histograms (DVHs) were analyzed for the heart and ipsilateral lung, comparing results for mDIBH versus FB plans. RESULTS: Eighty-seven patients were included for analysis. Of those, 66% received adjuvant chemotherapy with cardiotoxic agents. The mean dose for the whole breast was 47.6 Gy. There was a statistically significant decrease in all DVH parameters evaluated, favoring the delivery of mDIBH over FB plans. mDIBH plans significantly reduced cardiac mean dose (4.23 vs. 2.54 Gy; P<0.001), a relative reduction of 40%. In addition, there were significant reductions in all other heart parameters evaluated (ie, volume of heart treated, V30, V25, V20, V15, V10, and V5). mDIBH also significantly reduced lung dose, including a reduction of the left lung mean dose (9.08 vs. 7.86 Gy; P<0.001), a relative reduction of 13%, as well as significant reduction of all lung DVH parameters evaluated. CONCLUSIONS: To date, this series represents the largest experience utilizing mDIBH to reduce cardiac irradiation during left-sided breast cancer treatment. Statistically significant reductions in all heart and lung DVH parameters were achieved with mDIBH over FB plans. mDIBH, for the treatment of left-sided breast cancer, is a proven technique for reducing cardiac dose that may lead to reduced cardiotoxicity and can be routinely integrated into the clinic.
PURPOSE: Moderate deep inspiration breath-hold (mDIBH), using an Active Breathing Control device, has been used in our clinic since 2002 to reduce cardiac dose for patients receiving left-sided breast irradiation. We report our routine use of the mDIBH technique in clinically localized breast cancer, treated to the intact breast, reconstructed breast, or chest wall. MATERIALS AND METHODS: Ninety-nine patients with left-sided breast cancer were evaluated for Active Breathing Control treatment, of which, 87 patients were treated with mDIBH. Plans for both the free-breathing (FB) and mDIBH computed tomography scans were evaluated. Dose-volume histograms (DVHs) were analyzed for the heart and ipsilateral lung, comparing results for mDIBH versus FB plans. RESULTS: Eighty-seven patients were included for analysis. Of those, 66% received adjuvant chemotherapy with cardiotoxic agents. The mean dose for the whole breast was 47.6 Gy. There was a statistically significant decrease in all DVH parameters evaluated, favoring the delivery of mDIBH over FB plans. mDIBH plans significantly reduced cardiac mean dose (4.23 vs. 2.54 Gy; P<0.001), a relative reduction of 40%. In addition, there were significant reductions in all other heart parameters evaluated (ie, volume of heart treated, V30, V25, V20, V15, V10, and V5). mDIBH also significantly reduced lung dose, including a reduction of the left lung mean dose (9.08 vs. 7.86 Gy; P<0.001), a relative reduction of 13%, as well as significant reduction of all lung DVH parameters evaluated. CONCLUSIONS: To date, this series represents the largest experience utilizing mDIBH to reduce cardiac irradiation during left-sided breast cancer treatment. Statistically significant reductions in all heart and lung DVH parameters were achieved with mDIBH over FB plans. mDIBH, for the treatment of left-sided breast cancer, is a proven technique for reducing cardiac dose that may lead to reduced cardiotoxicity and can be routinely integrated into the clinic.
Authors: M Zambetti; A Moliterni; C Materazzo; M Stefanelli; S Cipriani; P Valagussa; G Bonadonna; L Gianni Journal: J Clin Oncol Date: 2001-01-01 Impact factor: 44.544
Authors: Lori J Pierce; James B Butler; Mary K Martel; Daniel P Normolle; Tod Koelling; Robin B Marsh; Allen S Lichter; Benedick A Fraass Journal: Int J Radiat Oncol Biol Phys Date: 2002-04-01 Impact factor: 7.038
Authors: L L Kestin; M B Sharpe; R C Frazier; F A Vicini; D Yan; R C Matter; A A Martinez; J W Wong Journal: Int J Radiat Oncol Biol Phys Date: 2000-12-01 Impact factor: 7.038
Authors: Rahul Roychoudhuri; David Robinson; Venkata Putcha; Jack Cuzick; Sarah Darby; Henrik Møller Journal: BMC Cancer Date: 2007-01-15 Impact factor: 4.430
Authors: Harriet Eldredge-Hindy; Virginia Lockamy; Albert Crawford; Virginia Nettleton; Maria Werner-Wasik; Joshua Siglin; Nicole L Simone; Kulbir Sidhu; Pramila R Anne Journal: Pract Radiat Oncol Date: 2015 Jan-Feb
Authors: Jacob S Witt; Robert W Gao; Lisa J Sudmeier; Stephen A Rosenberg; David M Francis; Charles R Wallace; Rupak K Das; Bethany M Anderson Journal: Brachytherapy Date: 2018-09-24 Impact factor: 2.362
Authors: M E Mast; M W Heijenbrok; M L van Kempen-Harteveld; A L Petoukhova; A N Scholten; R Wolterbeek; J H M Schreur; H Struikmans Journal: Strahlenther Onkol Date: 2016-08-17 Impact factor: 3.621
Authors: Thomas Mulliez; Liv Veldeman; Tom Vercauteren; Werner De Gersem; Bruno Speleers; Annick Van Greveling; Dieter Berwouts; Vincent Remouchamps; Rudy Van den Broecke; Wilfried De Neve Journal: Radiat Oncol Date: 2015-01-09 Impact factor: 3.481
Authors: María Adela Poitevin-Chacón; Rubí Ramos-Prudencio; José Alfonso Rumoroso-García; Alejandro Rodríguez-Laguna; Julio Cesar Martínez-Robledo Journal: Rep Pract Oncol Radiother Date: 2019-12-19